Saredutant

Saredutant

Clinical data
ATC code	none
Identifiers
IUPAC name N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
CAS Number	142001-63-6
PubChem (CID)	104974
IUPHAR/BPS	2111
ChemSpider	94726
ChEMBL	CHEMBL308148
ECHA InfoCard	100.111.408
Chemical and physical data
Formula	C31H35Cl2N3O2
Molar mass	552.5345 g/mol
3D model (Jmol)	Interactive image
SMILES Clc1ccc(cc1Cl)[C@H](CCN3CCC(c2ccccc2)(NC(=O)C)CC3)CN(C(=O)c4ccccc4)C
InChI InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1 Key:PGKXDIMONUAMFR-AREMUKBSSA-N
(what is this?)  (verify)

Saredutant (SR-48,968) is a drug that acts as a NK₂ receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.^[1]

See also

• GR-159,897
• Ibodutant
• Nepadutant

References

1. http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009